Ask about this productRelated genes to: 6G5 COMP
- Gene:
- COMP NIH gene
- Name:
- cartilage oligomeric matrix protein
- Previous symbol:
- PSACH, EDM1, EPD1
- Synonyms:
- MED, THBS5
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-24
- Date modifiied:
- 2016-10-05
Related products to: 6G5 COMP
(4S)_4_Cyclohexyl_[(4_phenylbutyl)phosp Fosinopril related comp(R)_glycolic acid, compound with (S)_1,2, (R)_glycolic acid, comp(R)_glycolic acid, compound with [S_(R,S (R)_glycolic acid, comp(RS)_9_Fluoro_2,3_dihydro_3_methyl_7_or Ofloxacin related comp(S)_glycolic acid, compound with (R)_1,2, (S)_glycolic acid, comp1H_benzotriazole, compound with morph 1H_benzotriazole, comp1_(4_(5_Cyclohexyl_1H_tetrazol_5_yl)butox Cilostazol related comp1_[(2_Chlorophenyl)(methylimino)methyl] Ketamine related comp2,4_diethylbenzenesulphonic acid, comp 2,4_diethylbenzenesulp2_(Diphenylmethyl)thioacetamide Modafinil related comp2_Aminoethanol, compound with bis[2_[2( 2_Aminoethanol, comp3,3_bis(4_hydroxyphenyl)phthalide, comp 3,3_bis(4_hydroxypheny3_(3,4,6_Tirhydroxyphenyl)_alanine Levodopa related comp4,_dimethylbenzenesulphonic acid, comp 4,_dimethylbenzenesulp4,_dimethylbenzenesulphonic acid, comp 4,_dimethylbenzenesulp Related articles to: 6G5 COMP
- Network meta-analysis (NMA) is an evidence synthesis approach that combines direct and indirect evidence to estimate the relative effects of multiple treatments, including comparisons for which head-to-head clinical trial evidence is unavailable. Although methodological and reporting guidelines for NMAs and their accompanying systematic reviews are well established, we posit that such guidelines are not always followed in practice. In this narrative perspective, we provide a concise overview of key guidelines for conducting and reporting systematic reviews and NMAs and critically appraise two recent NMAs in chronic migraine that deviate from these recommendations. While a broader systematic review was not undertaken and the identified shortcomings of these two NMAs may not be representative of the wider NMA landscape in the neurology literature, we nevertheless encourage readers of published systematic reviews and NMAs to carefully evaluate the underlying data and methods used in evidence synthesis and to interpret findings with appropriate caution, favoring analyses conducted in accordance with rigorous best practice standards. - Source: PubMed
Publication date: 2026/09/22
Ailani JessicaSaffore Christopher DUbamadu IfeanyiPerni StefanoChertavian ElizabethCollins Eric BWang Si-Tien - - Source: PubMed
- - Source: PubMed
- Doxorubicin is commonly used in the treatment of canine lymphoma and other malignancies but is associated with adverse effects, including gastrointestinal toxicity and myelotoxicosis. Previous veterinary studies have suggested that prophylactic antimicrobial administration may reduce chemotherapy-associated toxicity and hospitalisation. However, the potential benefits of prophylactic antimicrobials must be balanced against risks, including antimicrobial resistance and dysbiosis. This retrospective study evaluated the effect of prophylactic trimethoprim-sulfadiazine administration on gastrointestinal and haematologic adverse events in dogs with high-grade multicentric lymphoma receiving doxorubicin for the first time. Medical records from three referral hospitals in Queensland, Australia were reviewed for dogs treated between January 2008 and November 2025. Adverse events occurring within 14 days of doxorubicin administration were retrospectively graded using the Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events. Sixty dogs met the inclusion criteria, including 21 dogs receiving prophylactic TMS and 39 receiving no prophylactic antibiotics. Gastrointestinal toxicity occurred in 14/21 (66.7%) dogs receiving TMS compared with 13/39 (33.3%) dogs receiving no antibiotics (p = 0.013). After controlling for lymphoma stage, prophylactic TMS administration was associated with a 3.69-fold increase in the odds of GI toxicity (95% CI 1.13-12.11, p = 0.031). No significant differences were identified between groups in severity of GI toxicity, haematologic toxicity, neutropenia or hospitalisation rates. Prophylactic TMS administration during doxorubicin chemotherapy was associated with increased GI toxicity in this cohort, contrasting with previous reports and supporting the need for prospective evaluation of prophylactic antimicrobial use in contemporary geographically distinct canine chemotherapy populations. - Source: PubMed
Publication date: 2026/09/21
Madden Emily JayneChan Catherine - 1-[F]Fluoroethyl-indole propionic acid (1-[F]-IPA), a fluorinated analogue of indole-3-propionic acid (IPA), shows considerable promise as a PET tracer for imaging BxPC-3 pancreatic cancer xenografts. In the present study, we report a straightforward automated synthesis protocol that employs cartridge-based purification, providing 1-[F]-IPA in a form suitable for human use. This method was developed in compliance with good manufacturing practice (GMP) guidelines, and the final product meets the established release specifications for radiopharmaceuticals. The automated synthesis was carried out via a two-step, one-pot procedure, which involved [F]fluorination of methyl 1-(2-tosyloxyethyl)-1H-indole-3-propionate, subsequent hydrolysis with sodium hydroxide, and purification using a series of commercially available solid-phase extraction cartridges, thereby eliminating the need for preparative high-performance liquid chromatography (preparative HPLC). Using this one-pot approach on a modified commercial GE TRACERlab FX-FN radiosynthesis module, the final product was obtained with high uncorrected radiochemical yields (> 35 %) and radiochemical purity (> 95 %). Collectively, these results establish the GE TRACERlab FX-FN radiosynthesis module as a robust, flexible, and cost-effective platform for the routine clinical production of 1-[F]-IPA. - Source: PubMed
Dong WeixuanShen CongChang RuxiZhang ZheweiNiu ChenDuan Xiaoyi